Table 1.

DFS Overall and in Stratification Subgroups

		6-yr DFS	Hazard Ratio
			L+T vs T
			T→L vs T
Overall	L+T	85%	0.86 (95% CI, 0.74–1.00)
	T→L	84%	0.93 (95% CI, 0.81–1.08)
	T	82%
Design-1	L+T	83%	0.83 (95% CI, 0.69–1.00)
	T→L	82%	0.87 (95% CI, 0.73–1.05)
	T	79%
Design-2/2B	L+T	87%	0.92 (95% CI, 0.72–1.18)
	T→L	85%	1.05 (95% CI, 0.82–1.33)
	T	86%
Hormone receptor positive	L+T	85%	0.91 (95% CI, 0.75–1.11)
	T→L	85%	0.90 (95% CI, 0.74–1.10)
	T	83%
Hormone receptor negative	L+T	84%	0.80 (95% CI, 0.64–1.00)
	T→L	82%	0.97 (95% CI, 0.79–1.20)
	T	80%
pN0	L+T	91%	0.91 (95% CI, 0.67–1.22)
	T→L	90%	1.02 (95% CI, 0.76–1.36)
	T	89%
pN1	L+T	87%	0.78 (95% CI, 0.58–1.05)
	T→L	87%	0.76 (95% CI, 0.57–1.02)
	T	84%
pN2–3	L+T	75%	0.92 (95% CI, 0.71–1.18)
	T→L	71%	1.09 (95% CI, 0.86–1.39)
	T	73%

DFS: disease-free survival

L+T: trastuzumab concurrently with lapatinib

T→L: trastuzumab followed by lapatinib

T: trastuzumab alone